PDS0301 (also referred to as PDS01ADC or NHS-IL12) — Full data
Q1/Q2-2027
Q1/Q2-2027 NCI-led - Colorectal cancer with liver metastases (Final data readout)Source filing
PDSB biotech catalysts & pipeline
PDS BIOTECHNOLOGY CORP · Data as of 2026-10-25
Upcoming catalysts
PDS0301 (also referred to as PDS01ADC or NHS-IL12) — Full data
Q2/Q3-2027
Q2/Q3-2027 Metastatic castration resistant prostate cancer (Final data readout)Source filing
PDS0301 (also referred to as PDS01ADC or NHS-IL12) — Clinical data readout
Q4 2026
Five PDS0301 data readouts anticipated between Q4 2026 and Q2 2028 across biochemically recurrent prostate cancer, metastatic castration-resistant prostate cancer, colorectal cancer with liver metastases, and Kaposi sarcoma microsatellite stable (MSS) or mismatch repair-proficient (pMMR) diseaseSource filing
PDS0301 (also referred to as PDS01ADC or NHS-IL12) — Interim data
Oct 2026–Mar 2027
Q4-2026/Q1-2027 Biochemically recurrent prostate cancer (Interim readout)Source filing
PDS0301 (also referred to as PDS01ADC or NHS-IL12) — Full data
Q4-2027
Q4-2027 Biochemically recurrent prostate cancer (Final data readout)Source filing
PDS0301 (also referred to as PDS01ADC or NHS-IL12) — Interim data
Q2-2028
Q2-2028 Phase 3 – Colorectal cancer with liver metastases (Interim data readout)Source filing
PDS01ADC — Conference presentation
2H 2026
PDS01ADC + HAIP Stage 1 Cholangiocarcinoma PDS01ADC + Enzalutamide vs Enzalutamide Biochemically Recurrent Prostate cancer PDS01ADC + Docetaxel Castration Resistant Prostate cancer Final Data ReadoutPDS01ADC + HAIP Colorectal cancer PDS0101 + CRT Phase 2 data publication Cervical cancer VERSATILE-003 (Head and neck cancer) 2Q 2026 PDS01ADC + HAIPPreliminary data publicationColorectal cancer16 Upcoming Catalysts CRT = Chemoradiotherapy PFS = Progression free survival PHASE 2 TRIALS 2H 2026 1H 2027 2H 2027 1Q 2026 PDS01ADC + docetaxel in metastatic castration resistant prostate cancerPreliminary data publication15 Adoption of Amended Protocol (FDA)Source filing